CClinicalTrials.gg
CompletedNCT07806396Updated Sep 23, 2026

Effect of AI-Supported Virtual Patient Chatbot Training on Nursing Students' Self-Perceived Clinical Decision-Making and Gynecological Cancer Knowledge

An interventional study of AI-Supported Educational Virtual Patient Chatbot Platform in Nursing Education, Clinical Decision-making and Gynecologic Cancers, sponsored by Sakarya University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Sakarya University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized controlled trial evaluated the effects of structured case-based training delivered through an artificial intelligence-supported educational virtual patient chatbot platform on nursing students' gynecological cancer knowledge and self-perceived clinical decision-making. Third-year undergraduate nursing students who had completed the Obstetrics and Gynecology Nursing course were randomly assigned in a 1:1 ratio to an intervention group or an assessment-only wait-list control group. The intervention group completed five AI-supported virtual patient training scenarios during a two-week access period, followed by a common virtual patient assessment. The control group completed the same virtual patient assessment without access to the training scenarios during the study assessment period. Knowledge and self-perceived clinical decision-making were assessed at baseline and immediately after the assigned study procedures. Virtual patient performance was assessed once at the final assessment.

02

Conditions studied

  • Nursing Education
  • Clinical Decision-making
  • Gynecologic Cancers
  • Chatbot-Based Training

Keywords

  • Artificial Intelligence
  • Chatbot
  • Nursing Students
  • Virtual Patient
  • Gynecologic Oncology
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Enrolled as a third-year undergraduate nursing student.
  • Successfully completed the Obstetrics and Gynecology Nursing (Women's Health and Diseases Nursing) course.
  • Volunteered to participate and provided digital informed consent.

Exclusion criteria

Exclusion Criteria:

- No additional exclusion criteria.

04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    AI-Supported Virtual Patient Chatbot Training Group

    Participants received access to five sequential AI-supported educational virtual patient scenarios addressing cervical, endometrial, ovarian, vulvar, and vaginal cancers. The scenarios were completed during a two-week access period. Participants responded in free text, received immediate individualized formative feedback, and were allowed up to three response attempts per scenario. After completing all five training scenarios, participants completed the common virtual patient assessment and the immediate post-intervention outcome assessments.

    Other: AI-Supported Educational Virtual Patient Chatbot Platform

  • No intervention
    Assessment-Only Wait-List Control Group

    Participants did not receive access to the AI-supported training scenarios during the outcome assessment period. They completed the baseline assessments, the same common virtual patient assessment as the intervention group, and the immediate post-assessment knowledge and clinical decision-making measures. After completing all study outcome assessments, they were granted access to the AI-supported educational scenarios.

Interventions

  • OtherAI-Supported Educational Virtual Patient Chatbot Platform

    A web-based educational platform integrating structured gynecological oncology scenarios, AI-supported virtual patient interaction, predefined performance criteria, sequential progression, and immediate individualized formative feedback. Participants completed five training scenarios during a two-week access period. The platform used the Claude Sonnet 4 model, API identifier claude-sonnet-4-20250514, throughout the study.

05

What researchers measure

Primary outcomes

  1. Change in Clinical Decision Making in Nursing Scale-Turkish Version (CDMNS-Tr) Score

    The CDMNS-Tr is a 40-item scale assessing self-reported clinical decision-making. Items are rated on a 5-point Likert scale ranging from 1 (never) to 5 (always), with eighteen negatively worded items being reverse-scored. Total scores range from 40 to 200, with higher scores indicating a higher self-perception of clinical decision-making abilities.

    Time frame: Baseline, before access to any group-specific study procedure, and immediately after completion of the assigned study procedures.

Secondary outcomes

  1. Change in Gynecological Oncology Knowledge Test Total Score

    The researcher-developed test consists of 15 multiple-choice items assessing the pathophysiology, clinical manifestations, diagnosis, treatment, complications, and nursing care of gynecological cancers. Correct answers are scored as 1 and incorrect or unanswered items as 0. Total scores range from 0 to 15, with higher scores indicating greater knowledge. Change was evaluated by comparing baseline and immediate post-intervention total scores.

    Time frame: Baseline, before access to any group-specific study procedure, and immediately after completion of the assigned study procedures, within approximately two weeks after baseline.

06

Study locations

1 site
  • Sakarya University
    Sakarya, Turkey 54050, Turkey (Türkiye)
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07806396
Lead sponsor
Sakarya University
Responsible party
Ahsen Demirhan (Research Assistant, Sakarya University) — Principal investigator
First posted
Sep 8, 2026
Start date
Jun 29, 2026
Primary completion
Aug 2, 2026
Completion
Aug 2, 2026
Last update
Sep 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion